Psoriasis

Researchers found that psoriasis correlated with nonalcoholic fatty liver disease among adults, based on data from the National Health and Nutrition Examination Survey.

Analysis of multiple trials showed that treatment with Bimzelx for moderate to severe psoriasis was well-tolerated, aside from an increased incidence of mild to moderate oral candidiasis.

CLEVELAND — Inflammation that causes psoriasis also impacts cardiovascular health, according to Nehal Mehta, MD, MSCE, FAHA, of the NIH.

CLEVELAND — At the Medical Dermatology Therapy Update II, Andrew Blauvelt, MD, MBA, gave an update on available psoriasis therapies and those on the horizon.

In this series of videos, April W. Armstrong, MD, MPH, discusses important takeaways from psoriasis sessions at this year’s American Academy of Dermatology Annual Meeting.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.

The FDA has approved Vtama cream for the treatment of plaque psoriasis in patients with mild, moderate or severe disease, Dermavant Sciences announced.

Plaque psoriasis patients treated with deucravacitinib maintained improvement for up to 2 years, Bristol Myers Squibb announced in a press release.

Patients with psoriasis who were treated with ixekizumab were more likely to adhere to therapy compared with those treated with adalimumab over a 24-month period, according to a study.